Increased maternal serum activin A but not follistatin levels in pregnant women with hypertensive disorders
Increased maternal serum activin A but not follistatin levels in pregnant women with hypertensive disorders
复制标题
DOI：
10.1677/joe.0.1650157
复制
发表时间：
2000-04-01
影响因子：
4
通讯作者：
Petraglia, F
中科院分区：
文献类型：
--
作者：
D'Antona, D;Reis, FM;Petraglia, F
患有高血压的孕妇的母体血清中激活素 A 水平升高。由于卵泡抑素是激活素 A 的循环结合蛋白，本研究旨在评估妊娠最后三个月高血压患者的血清卵泡抑素和激活素 A 水平是否也发生变化。该研究设计是在学术产前护理单位进行的一项对照调查。将健康孕妇（对照组，n = 38）与患有妊娠高血压综合征（PIH，n = 18）或先兆子痫（n = 16）的患者进行比较。此外，该研究还纳入了与宫内生长受限相关的先兆子痫患者的子集（IUGR，n = 5）。在诊断时（患者）或随机产前检查时（对照）抽取母体血液样本，并使用特异性酶免疫测定法测定血清中卵泡抑素和激活素 A 的水平。通过转换为相同胎龄的健康对照的中位数（MoM）的倍数，对孕龄的激素浓度进行校正。对照组和患者之间的卵泡抑素水平没有差异，而 PIH (18 MoM)、先兆子痫 (4.6MoM) 和先兆子痫 + IUGR (3.2 MoM，P < 0.01，ANOVA) 患者的激活素 A 水平显着升高。 PIH 患者中激活素 A 与卵泡抑素的比率显着增加 (1.5 MoM)，在先兆子痫患者 (4.5 MoM) 和先兆子痫 + IUGR 组 (2.6 MoM) 中进一步增加。在对照受试者（r = 0.36，P < 0.05）和妊娠高血压患者（r = 0.46，P < 0.05）或先兆子痫患者（r = 0.61，P < 0.01）中，卵泡抑素水平与胎龄呈正相关，而激活素则与胎龄呈正相关。仅在健康对照组中 A 与胎龄相关（r = 0.69，P < 0.0001）。在 PIH 和先兆子痫患者中发现卵泡抑素明显正常且激活素 A 水平较高，这表明患有这些妊娠疾病的女性中未结合的、具有生物活性的激活素 A 有所增加。
Activin A levels are elevated in maternal serum of pregnant women with hypertensive disturbances. Because follistatin is a circulating binding protein for activin A, the present study was designed to evaluate whether serum follistatin and activin A levels also change in patients with hypertensive disorders in the last gestational trimester. The study design was a controlled survey performed in the setting of an academic prenatal care unit. Healthy pregnant women (controls, n = 38) were compared with patients suffering from pregnancy-induced hypertension (PIH, n = 18) or pre-eclampsia (n = 16). In addition, the study included a subset of patients with pre-eclampsia associated with intrauterine growth restriction (IUGR, n = 5). Maternal blood samples were withdrawn at the time of diagnosis (patients) or ma random prenatal visit (controls), and serum was assayed for follistatin and activin A levels using specific enzyme immunoassays. Hormone concentrations were corrected for gestational age by conversion to multiples of median (MoM) of the healthy controls of the same gestational age. Follistatin levels were not different between controls and patients, while activin A levels were significantly increased in patients with PIH (18 MoM), pre-eclampsia (4.6MoM), and pre-eclampsia + IUGR (3.2 MoM, P < 0.01, ANOVA). The ratio between activin.A and follistatin was significantly increased in patients with :PIH (1.5 MoM) and was further increased in patients with pre-eclampsia (4.5 MoM) and in the group with preeclampsia + IUGR (2.6 MoM). Follistatin levels were positively correlated with gestational age in control subjects (r = 0.36, P < 0.05) and in patients with PIH (r = 0.46, P < 0.05) or pre-eclampsia (r = 0.61, P < 0.01), while activin. A correlated with gestational age only in the healthy control group (r = 0.69, P < 0.0001). The finding of apparently normal follistatin and high activin A levels in patients with PIH, and pre-eclampsia suggests that unbound, biologically active, activin A is increased in women with these gestational diseases.